bluuebunny/crossref_metadata_2025_split huggingface dataset:
P0150EFFECT OF SEROTONIN REUPTAKE INHIBITORS (SSRIS) AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) ON BLOOD PRESSURE VARIABILITY USING 24 HOURS AMBULATORY BLOOD PRESSURE MONITORING
Authors: Aslam Nabeel , Memon Sobia , Wadei Hani , Niazi Shehzad 
Published: June 2020

Abstract

Background and Aims
Hypertension (HTN) and psychiatric disorders frequently co-exist in general population. Serotonin re-uptake inhibitors (SSRIs) and serotonin-norepinephrine re-uptake inhibitors (SNRIs) affect serotonin and norepinephrine and may lead to variation in blood pressure (BP). There is paucity of data on blood pressure variations using 24 hours ambulatory blood pressure monitoring (ABPM) with the use of SSRIs/NSRIs.

Method
Subjects who underwent psychiatric evaluation and ABPM within six month of each other between 1/1/2012 to 12/31/2016 at Mayo Clinic Florida were identified using billing data. Demographics, co-morbidities, medications, ABPM, and laboratory results were retrospectively collected from medical records. Subjects were divided into groups – subjects with no psychiatric diagnosis and no psychiatric medicine (Group 1) and subjects with psychiatric diagnosis and on SSRIs/NSRIs (Group 2). BP systolic and diastolic levels (day time, night time) were compared between groups controlling for age, sex, race, presence or absence of HTN, diabetes mellitus (DM) and smoking. Single and multivariable linear regression models were used to analyze group differences.

Results
Total of 367 subjects met inclusion criteria – Group 1=135; Group 2=232. The subjects in group 2 were older (median age 57 yrs vs 47 yrs p&lt;0.001), white (69.8 vs 60% p=0.002), smokers (15.9 vs 3.0% p&lt;0.001), history of HTN (62.5 vs 9.6%), and DM (21.1% vs 0%). ABPM showed that subjects in group 2 had higher median daytime systolic BP (131 vs 124), higher median night time systolic BP (120 vs 110), and higher median night time diastolic BP (68 vs 63). Multivariable linear regression controlling for age, sex, race, presence or absence of HTN, DM, and smoking showed that use of SSRIs/NSRIs (group 2) was significantly associated with higher night time systolic BP (8.36 mm; 95% CI 4.2, 12.5; p &lt;0.0001) and higher night time diastolic BP (4.6 mm, 95% CI 1.9, 7.29, p=0.001). On subgroup analysis comparing subjects with use of SSRIs vs NSRIs, there was no statistically significant difference in the daytime or night time systolic or diastolic BP.

Conclusion
Use of SSRIs and NSRIs are associated with higher nocturnal systolic and diastolic BP, which can potentially increase the risk of adverse cardiovascular outcome in this population. Higher nocturnal BP may be due to ongoing sympathetic activation during sleep with serotonin and norepinephrine with the use of SRRIs and NSRI. Further well designed prospective studies using ABPM are needed to determine the risk of nocturnal hypertension with the use of SSRIs/NSRIs that could have potential adverse cardiovascular outcome.
P0165HYPERTENSION IN OVERWEIGHT AND OBESE CHILDREN: IMPACT ASSESMENT OF ABPM PARAMETERS
Authors: Apuzzo Diletta , Annicchiarico Petruzzelli Luigi , Ascione Serena , Corcione Adele , Pedoto Deianira , Barra Giuseppina , Rocco Maria Chiara , Pecoraro Carmine , Malgieri Gabriele 
Published: June 2020

Abstract

Background and Aims
We describe the relationship between overweight and obesity and Hypertension on ABPM.

Method
We conducted a cross-sectional study using a database of patients aged 6-16 years, who had undergone 24h ABPM from December 2002 through December 2016. ABPM were performed using the validated device Spacelab 90217. Were evaluated the 24h MAP, daytime MAP, nocturnal MAP, systolic and diastolic load, MAP Systolic and Diastolic. Subjects were grouped by BMI Z-score into overweight (&gt;1&lt;2), obese (BMI Z-score &gt;2&lt;3) and severe obese (BMI Z-score &gt;3). A total of 1016 patients were enrolled and recorded n.1210 ABPMs. Obese pts were 202 (19.8%); 126 M;76F;median age 10,2 y. Overweight childrens were 97 (11.9%);52 M;45F;median age 8,4y.

Results
Among overweight childrens (BMI Z-Score &gt;1&lt;2): 12 (12.3%) had hypertension, 22 (22.6%) pre-hypertension, 15 (15.4%) MH; non dipping pattern was recorded in 26 (52%). 48 were normotensive. Among obese childrens, 122 had hypertension (60.3%): 24 pts had Masked Hypertension (19.6%); 72 (59.0%) had severe ambulatory hypertension with BMI z-score &gt;3 (mean 3.8) ,and in this category all pts were both systolic and diastolic non dipping. 32 (64%) obese with BMI z-score &gt;2, &lt;3 were non-dipping. Diastolic load was significantly higher (p&gt;0,0001) in severe obese. 28 pts had ambulatory prehypertension (13.8%), 11 pts had White Coat Hypertension (4.9%).41 pts had normotension (20.2%).

Conclusion
The severity of ambulatory hypertension increased with increased BMI Z-score. The non-dipping status is associated, not only with higher BMI Z-score, but was present in overweight and obese with BMI z-score &gt;2&lt;3 also. ABPM is an effective tool that should become routine in all obese patient, but also in overweight childrens, which may lead to better treatments and prevention methods.
P0170ETHANOL EXTRACT OF LIRIODENDRON CHINENSE(HEMSL.) SARG BARKS ALLEVIATES HYPERURICEMIC NEPHROPATHY VIA MEDIATING RENAL FIBROSIS AND INFLAMMATION
Authors: Pan Jing , Ma Liang , Fu Ping 
Published: June 2020

Abstract

Background and Aims
The barks of Liriodendron Chinense (Hemsl.) Sarg is used in folk for expelling “wind and dampness”, alleviating rheumatic arthralgia in traditional Chinese medicine. The aim of the study was to evaluate the protective effect of ethanol extract of the barks of Liriodendron Chinense (Hemsl.) Sarg (EELC) in a mouse model of hyperuricemic nephropathy (HN) and the mechanisms involved.

Method
EELC at a respective dose of 250 mg/kg/d or 500 mg/kg/d were orally administered to HN mice induced by a mixture of adenine (160 mg/kg/d)/potassium oxonate (2.4 g/kg/d) for 21 days. At the end of the treatment, serum uric acid, kidney functions (serum creatinine, BUN and urine microalbumin), 24-h urine uric acid excretion, as well as kidney pathological changes were investigated by biochemical assay, histopathological score, immunofluorescence and histochemistry, RT-PCR, and western blotting analysis.

Results
Oral administration of EELC to HN mice lowered serum uric acid, improved renal functions and attenuated renal fibrosis, especially the high-dose of EELC. EELC treatment also inhibited the activation of NF-κB, ASK1/JNK/c-Jun, JAK2/STAT3 signaling pathways and reduced the release of pro-inflammatory cytokine TNF-α in the kidneys of HN mice. Furthermore, EELC remarkably increased urine uric acid excretion of HN mice, which may be achieved by the upregulation of organic anion transporter 1 (OAT1), OAT3 and ATP-binding cassette subfamily G member 2 (ABCG2) proteins.

Conclusion
EELC alleviated the progression of HN by suppressing the activation of NF-κB, ASK1/JNK/c-Jun and JAK2/STAT3 signaling pathway, reducing the infiltration of inflammatory factors and uric acid accumulation in the kidney.

Figure
Date are represented as the mean ± SD. *p&lt;0.05,**p&lt;0.01,***p&lt;0.001, ****p&lt;0.0001 vs. control, §p &lt;0.05, §§p&lt;0.01, §§§p&lt;0.001,§§§§p&lt;0.0001 vs. model.
P0172ARE FREQUENT STONE REMOVAL PROCEDURES IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 3 (PH 3) RELATED TO DECLINE IN KIDNEY FUNCTION?
Authors: Hoppe Bernd , Martin Higueras Cristina , Beck Bodo B , Zaniew Marcin , Sikora Przemyslaw 
Published: June 2020

Abstract

Background and Aims
PHIII is seen as the less problematic type of autosomal recessive inherited PH. This group of disorders in glyoxylate metabolism is clinically characterized by recurrent urolithiasis and/or progressive nephrocalcinosis, and, in type I and II, end-stage renal failure. The cause of PHIII was identified only in 2010 and unlike in PHI/II a remarkable low prevalence of symptomatic adults was observed, hence long-term clinical data are scarce. This phenomenon is commonly attributed to reduced penetrance of causative hydroxy-oxo-glutarate aldolase 1 gene (HOGA1) variants and a still unexplained tendency for clinical remission with age. Most PHIII patients present in early childhood with recurrent urolithiasis and undergo (repeated) stone removal procedures. We now hypothesized that repeated stone removal procedures may be associated with decline in kidney function.

Method
We retrospectively analyzed clinical and laboratory data of 41 genetically confirmed PHIII patients (0.5-29.3 years of age, with (20 different) biallelic mutations in the HOGA1 gene). Period of follow-up ranged from just diagnosed to 22 years.

Results
Recurrent urolithiasis was most prominently found in the first 3 years of life (&gt;25% of patients). Not all patients experienced clinical remission, 3/6 patients &gt; 20 years of age have ongoing kidney stone development. In addition, patients presented with nephrocalcinosis and/or urolithiasis. A high amount of stone removal procedures during the first years, but also later in life was observed. Urinary oxalate excretion is significantly elevated, and within the range of PHI/II. A decline in kidney function was observed, which is related to a decreased clearance of oxalate (figure). Two patients each post multiple stone removal procedures had CKD stages 2 or 3. Seven further patients had CKD stage 2, which was not related to stone removal.

Conclusion
PHIII is said to be the most favorable PH type, but early diagnosis is mandatory to treat the patients adequately and to avoid repeated stone removal procedures, which may have an influence on decline in kidney function. This decline may also be related to hyperoxaluria per se, as reported for PHI and II.
P0173CHRONIC KIDNEY DISEASE IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 3 (PH 3) - A LITERATURE META-ANALYSIS
Authors: Hoppe Bernd , Martin Higueras Cristina 
Published: June 2020

Abstract

Background and Aims
Primary Hyperoxaluria type 3 (PH3) is considered the most benign phenotype of all forms of primary hyperoxaluria. Being it typical that patients with PH type 1 and 2 develop chronic kidney disease (CKD) or end-stage renal disease (ESRD), it appears to be more or less uncommon that patients with PH3 are on risk of CKD and even do not develop ESRD. We now aimed to determine the number of PH3 patients reported to have any kind of CKD.

Method
We performed a literature meta-analysis, searching in PubMed with the following keywords: primary hyperoxaluria, PH, primary hyperoxaluria type III, PH III or PH3.

Results
We found 154 patients in 18 relevant papers published between 2010-2019. The number of patients reported per paper ranged from 1-2 up to 38 patients. Age of diagnosis/disease onset ranged from 1 month to 48 years of life. Most of the patients suffered recurrent urolithiasis, most often during the first years of life, but recurrent kidney stone episodes were also found later in life. In 77 patients no adequate information was provided with regard to renal function. In 14 patients it was only mentioned that they did not have renal failure at time of reporting. Five patients were said to be in stable kidney function without providing eGFR or serum creatinine levels. In 62 patients we were able to assess kidney function at time of paper and only in 41 patients (27%) eGFR values were available (18-232 ml/min/1.73m2). Only one patient in ESRD was reported, however the clear reason for ESRD is not provided in the reference. One patient with CKD stage 4-5 was found with an eGFR of 18 ml/min/ 1.73m2, after heminephrectomy was performed due to renal carcinoma. He was diagnosed at age 78 but has had recurrent kidney stones over a period of 30 years. Other three patients had stage 2-3 kidney disease (eGFR 53-61.8 ml/min/1.73m2). CKD stages 1-2 were found in 17 patients (eGFR from 77-104 ml/min/1.73m2). In six patients follow-up measures were available, as their data were included in two papers (4 years apart from each other). Here, in one patient eGFR significantly declined from 134 to 68.1 ml/min/1.73m2, while in the other 5 it remained stable over time.

Conclusion
Based on this non-comprehensive dataset, the majority of PH3 patients remain in stable kidney function over time. However, there is a massive bias in the data published, as data on kidney function is mostly not adequately reported. Nevertheless, CKD was observed in 13.7% of PH3 patients, and even one patient with ESRD was described. Also, one PH3 patient had died at age 4 months, but because of respiratory failure and not because of PH. Thus, as true long-term follow-up data is still missing, we nevertheless suspect PH3 not being as benign as currently being reported.
P0174NEPHROPROTECTIVE ACTIVITY OF GOSSYPETIN THROUGH INHIBITORY EFFECT ON XANTHINE OXIDASE, NUCLEAR FACTOR KAPPA B (NF-KB) AND SOLUBLE EPOXIDE HYDROLASE (SEH): IN-VITRO AND IN-SILICO EXPERIMENT
Authors: Patel Dinesh Kumar , Patel Kanika 
Published: June 2020

Abstract

Background and Aims
Oxidative stress and inflammation is the major contributor of kidney injury and the drugs which have antioxidant and anti-inflammatory activity could protect kidney against renal damage. Mechanisms involved in renal failure include oxidative stress, inflammation and apoptosis which lead myoglobinemia, myoglobinuria and cast formation. Inflammatory mediators such as IL-1, ICAM-1 and TNFα also play important role in renal failure. Excess production of uric acid can cause serious consequence in hyperuricemia and xanthine oxidase (XO) catalyzes the oxidation of xanthine to uric acid. Protective effects of gossypetin in the management of kidney injury and related disorders have been investigated in the present work through inhibitory potential of gossypetin on nuclear factor kappa B (NF-κB), soluble epoxide hydrolase (sEH) and XO.

Method
Present work described the medicinal importance of gossypetin with their beneficial effect on kidney disorder. In-silico molecular docking and dynamic experiments were carried out with gossypetin against nuclear factor kappa B (NF-κB) and soluble epoxide hydrolase (sEH). Further docking was also performed to investigate how gossypetin and the active site of XO fit together.

Results
From the analysis of the available data’s in the present work, it was found that gossypetin have protective effect against nephrotoxicity. Gossypetin also showed potent anti-inflammatory activity in kidney mesangial cells which further support application of natural compounds on nephritis treatment. Importance of gossypetin for preventing renal damage has been also emphasized due to its antioxidants potential. In-silico studies showed that, gossypetin exhibited a higher docking score against NF-κB and sEH. Docking studies revealed gossypetin surrounds the active sites of XO and reduces conversion of xanthine to uric acid.

Conclusion
Study revealed their antioxidant, anti-mutagenic, anti-atherosclerotic, anti-microbial and cytoprotective properties. The protective effect of gossypetin in kidney could be due to its antioxidant and anti-inﬂammatory activity through inhibition of NF-κB and sEH upregulation.
P0175DETERMINANTS OF RENAL PAPILLARY APPEARANCE IN RENAL STONE FORMERS: AN IN-DEPTH EXAMINATION
Authors: Bargagli Matteo , De Leonardis Rossella , Ragonese Mauro , Totaro Angelo , Pinto Francesco , Recupero Salvatore , Bassi PierFrancesco , Gambaro Giovanni , Ferraro Pietro Manuel 
Published: June 2020

Abstract

Background and Aims
Nephrolithiasis is a medical condition characterized by high prevalence among the general population both in Europe and in the U.S. and it is responsible for high costs reaching up to $10 billion per year. It is associated with specific comorbidities such as obesity, arterial hypertension, diabetes mellitus, metabolic syndrome and chronic kidney disease.
Kidney stones development is believed to start either from Randall’s plaques or from stone plugs. Both these lesions can be seen on renal papillary surfaces, but what promotes the formation of plaques and plugs is not entirely understood.
The aim of this study is to investigate the association between the urinary metabolic milieu and a published endoscopic papillary evaluation score (PPLA). We also evaluated the correlation of PPLA score with kidney stone recurrence during follow-up.

Method
We prospectively enrolled 31 stone forming patients who undergone retrograde intrarenal surgery procedures. Visual inspection of the accessible renal papillae was performed in order to calculate the PPLA score based on the appearance of ductal plugging, surface pitting, loss of papillary contour and Randall’s plaque extension.
Demographic information, blood samples, 24h urine collections and kidney stone events during follow-up were collected. Stone composition was analyzed using infrared-spectroscopy. Relative urinary supersaturations (RSS) for calcium oxalate (CaOx), calcium phosphate (CaPi) and uric acid (UA) were calculated using the Equil2 software. PPLA score &gt; 3 was defined as high.

Results
Median follow-up period was 11 (min/max 5, 34) months. PPLA score was inversely correlated with BMI (rho = −0.39, p = 0.035) and history of recurrent kidney stones (median PPLA 5.0 vs 2.5, p = 0.029), these results were confirmed when PPLA was considered as a categorical variable (median BMI 27 vs 24, recurrent stone disease 12 vs 62%, p= 0.006). Furthermore, high PPLA score was associated with lower odds of new kidney stone events during follow-up (OR 0.154, 95% confidence interval 0.024, 0.998, p = 0.05). No significant correlations were found between PPLA score, stone composition, blood parameters, 24h urine solute excretions and RSS for CaOx, CaPi and UA.

Conclusion
Different papillary abnormalities seem to be linked to specific mechanisms of stone formation. Although data regarding PPLA score are inconsistent, it may be a valid asset for both medical and surgical management of nephrolithiasis. Larger, long-term prospective clinical studies need to be conducted to assess the validity of PPLA score system in evaluating risk of stone recurrence.
P0177PREVALENCE AND RISK FACTORS OF HYPERURICEMIA IN THE BAI ETHNIC GROUP IN SOUTHWESTERN CHINA
Authors: GAO Chenni , DUAN Yuhua , JIA Liangqin , ZHANG Wen , REN Hong , XIE Jingyuan , CHEN Xiaonong 
Published: June 2020

Abstract

Background and Aims
The Bai ethnic group is one of the officially recognized minorities in the People's Republic of China, with a total population of 1.93 million. More than 80% of the Bai ethnic group live in Dali Bai Autonomous Prefecture in Yunnan Province. Because of their dietary habit and chronic exposure to high altitude, hyperuricemia is not rare among the Bai ethnic group. Hyperuricemia is not only related to the presence of hypertension, obesity and dyslipidemia, but also increases the risks of stroke, heart disease and chronic kidney disease. But the prevalence of hyperuricemia in the Bai ethnic group remains unclear.

Method
We collected the demographic information as well as laboratory test results of 1393 Bai ethnic people undergoing medical examination during Jan 2019 to Dec 2019 in the People's Hospital of Jianchuan County, Yunnan Province (average altitude 2300m). Written informed consent was obtained from all the participants. Hyperuricemia is defined as serum uric acid level superior to 360 μmol/L for female and 420 μmol/L for male. We investigated the prevalence of hyperuricemia and its risk factors in the Bai ethnic group in southwestern China.

Results
Of the 1393 participants enrolled in the study, the prevalence of hyperuricemia was 24.8%, and the prevalence was significantly higher in male gender (33.2% in men vs. 11.0% in women, P&lt;0.001). The prevalence of hyperuricemia increased from 19.2% among participants aged 30-40 years to 30.1% among participants aged 50 years and older (Fig 1). Also, the prevalence of hyperuricemia elevated from 17.2% among participants with normal body mass index (BMI) to 35.5% among those who were overweighed or obese (Fig 2). Interestingly, we found a positive correlation between hemoglobin level and serum uric acid (β=2.19, P&lt;0.01). Logistic regression analysis revealed main risk factors for hyperuricemia in the Bai ethnic group included age, sex, BMI, systolic blood pressure (SBP) and hemoglobin level.

Conclusion
Hyperuricemia is common in the Bai ethnic group. Its prevalence differs in different sex, age and BMI groups. Furthermore, polycythemia secondary to chronic exposure to high altitude may also contribute to the hyperuricemia.
P0183THE USE OF PCSK9 INHIBITORS COULD REDUCE PROTEINURIA IN CHRONIC KIDNEY DISEASE PATIENTS
Authors: Muñoz Ramos Patricia , Gil Giraldo Leydy Yohana , Reque Javier , Quiroga Borja , Alvarez Chiva Vicente 
Published: June 2020

Abstract

Background and Aims
Chronic kidney disease (CKD) is a cardiovascular risk factor per sé and enhances the risk of cardiovascular events. Dyslipidemia is one of the most studied risk factors and current guidelines recommend the universal treatment in CKD patients (not in dialysis) irrespective of low density lipoprotein (LDL) cholesterol level. However, the latest European Cardiology guidelines recommend monitoring LDL cholesterol to achieve levels lower than 70 mg/dl in CKD stage 3 and lower than 55 mg/dl in stages 4 and 5. Proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i) have opened a new era leading greater reduction of LDL cholesterol and subsequently cardiovascular events but real-life data is not available in CKD patients. The aim of the present study is analysing the evolution of renal function and proteinuria in a cohort of patients with PCSK9i.

Method
This is a retrospective study that included all the patients treated with PCSK9i in our centre. Inclusion criteria were the presence of CKD and dyslipidemia with indication of the use of PCSK9i (not reaching LDL target with maximum tolerated statin dose or intolerance for the use of statins). At baseline, epidemiological data and comorbidities were collected, as well as renal function using glomerular filtration rate (GFR) estimation with CKD-EPI equation, proteinuria (mg/g of creatinine) and lipid profile. During a one-year follow up, renal function, proteinuria, lipid profile and adverse events were collected and analysed.
Results: . Forty-one patients were included with a mean age of 70±10 years and 26 men (62%). Thirty-four patients (83%) had hypertension, 11 (27%) were diabetic, 19 (44%) had coronary disease, 8 (20%) history of heart failure, 3 (7%) peripheral vascular disease and 6 (15%) history of stroke. Regarding renal function, at baseline mean of creatinine was 1.3±0.5 mg/dl, GFR 54±19 ml/min/1.73m2 and proteinuria 456±215 mg/g. Lipid profile at baseline demonstrated an LDL cholesterol value of 163±58 mg/dl, triglycerides of 255±389 mg/dl and high density lipoprotein (HDL) of 53±14mg/dl.
During follow up, total cholesterol, LDL-cholesterol and triglycerides improved significantly (p&lt;0.001 for all in comparison to baseline values). GFR remained stable during the first year of follow up (CKD-EPI at 1 year 52±20 ml/min/1.73m2). Proteinuria improved at first month (235±71 mg/g), achieving stability at 3 months (124±44 mg/g), 6 months (176±94 mg/g) and 1 year (163±83 mg/g) (p for trend 0.02) (figure 1). No adverse events were registered during follow up, and two patients required hospitalization due to cardiovascular events.

Conclusion
The treatment of dyslipidemia with PCSK9i could decrease proteinuria in CKD patients via controlling lipoid nephrotoxicity. Clinical trials are needed to further investigate this effect.